**Introduction**

- **The PDS** is an innovative drug delivery system for the continuous delivery of a therapeutic agent in a sustained manner through the posterior capsule of the lens.
- It is approved by the US Food and Drug Administration (FDA) for the treatment of neovascular age-related macular degeneration (nAMD).
- In PDS nAMD trials (Ladder, Archway, Portal), 2.0% of patients receiving a ranibizumab implant experienced ≥ 1 episode of endophthalmitis in data reported to March 2021.

**Methods**

- In Ladder, patients received PDS (10, 40, or 100 mg/mL) with pre-intraocular (PIO), monthly intravitreal ranibizumab (0.5 mg/mL) or monthly PDS (Q24W) and monthly ranibizumab (1 mg/mL).
- In Archway, patients received PDS 100 mg/mL with fixed monthly exchanges every 24 weeks (PDS Q24W) or monthly ranibizumab (1 mg/mL).
- One month of PDS was compared with Ladder (nAMD) patients treated with pre-PDS 100 mg/mL, PIO or monthly intravitreal ranibizumab.
- Long-term safety was assessed using stated dates from all patients who received the PDS implant in Ladder, Archway, or Portal, regardless of dosage (1 mL; 500 mg/mL; 100 mg/mL), safety populations, with follow-up at 24, 42, and 60 months.

**Conclusions**

- **The safety and efficacy profiles of PDS Q24W,** if maintained, would be favorable.

**Purpose**

- To evaluate the long-term safety and efficacy of the PDS in patients with neovascular age-related macular degeneration (nAMD).
- To describe the key steps in the PDS implant insertion and refill-exchange procedures for maximizing successful patient outcomes.

**Figures and Tables**

1. Ladder to Portal: PDS Q24W Maintained Vision Through Month 48
2. Ladder to Portal: OPT Maintained From Baseline Through Month 48
3. A. Ladder to Portal: Over 90%,<sup>a</sup> of Patients Q24W Did Not Need Supplemental Treatment Before Each Refill-Exchange Procedure
4. Ocular AEs<sup>b</sup> Through an Average of 516 Weeks of Follow-Up (All-PDS Safety Population)
5. Implant Insertion Procedure: Meticulous Adherence to FDA-Approved Instructions for Use May Mitigate Risks Associated With the PDS
6. Refill-Exchange Procedure: Meticulous Adherence to FDA-Approved Instructions for Use Is Important for Successful Outcomes

---

**References**


**Financial Disclosures**

- None, I declare that I have no financial interests.

**Study and Product Disclosures**

- The authors declare that they have received no grants or funding to produce this research.

---

**Additional Information**

- This study was conducted in accordance with the tenets of the Declaration of Helsinki.
- All patients provided written informed consent before participating in the study. The study was approved by the appropriate institutional review board or ethics committee.
- The authors declare that they have received no grants or funding to produce this research.